Trials / Conditions / Bacterial Pneumonia

Bacterial Pneumonia

27 registered clinical trials studyying Bacterial Pneumonia — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Investigation of the Effects of Oxidized Antigens on the T-Cell Response and the Epigenetic Reprogramming of N NCT07386912	Research Center Borstel	—
Recruiting	A Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Polymyxin B and Colistin Methanesulfon NCT06966284	TTY Biopharm	—
Recruiting	Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CA NCT06804096	Dr. Md. Alimur Reza	Phase 4
Terminated	Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia NCT05531149	Biotest	Phase 3
Terminated	A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CM NCT05629741	Clarametyx Biosciences, Inc.	Phase 1
Completed	Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients NCT05417997	RAAS Nutritionals, LLC	Phase 3
Completed	Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia NCT04779242	Paratek Pharmaceuticals Inc	Phase 3
Unknown	Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID NCT04952337	Hannover Medical School	—
Terminated	Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia NCT03862040	Shionogi	Phase 1
Unknown	Multiplex Polymerase Chain Reaction in Postoperative Pneumonia After Thoracic Surgery NCT03752320	Assistance Publique - Hôpitaux de Paris	—
Completed	Cx611-0204 SEPCELL Study NCT03158727	Tigenix S.A.U.	Phase 1 / Phase 2
Completed	Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pne NCT02493764	Merck Sharp & Dohme LLC	Phase 3
Completed	Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13) NCT02531438	Paratek Pharmaceuticals Inc	Phase 3
Completed	Inhaled Corticosteroids in U-5 Children With Acute Respiratory Infection in Uganda: A Randomised Trial NCT01868113	Makerere University	Phase 3
Terminated	Clinical Trials to Reduce the Risk of Antimicrobial Resistance NCT01570192	University of Florida	Phase 2
Completed	Assessment of the Diagnostic Capacity of the Mini-broncho Alveolar Lavage Performed Through a Suction Catheter NCT00763620	Assistance Publique - Hôpitaux de Paris	N/A
Completed	Vitamin D Supplementation Prevents Elderly Pneumonia NCT00877422	Tohoku University	N/A
Withdrawn	Use of TREM-1 Protein to Differentiate Viral and Bacterial Pneumonias in Intubated Children NCT00645619	University of Texas Southwestern Medical Center	—
Completed	Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia NCT00621504	Forest Laboratories	Phase 3
Completed	An Effectiveness, Safety, and Microbiology Study of Doripenem in Patients With Nosocomial (Hospital-acquired) NCT00502801	PriCara, Unit of Ortho-McNeil, Inc.	Phase 2
Completed	Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia NCT00509106	Forest Laboratories	Phase 3
Completed	Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphyloc NCT00107952	Cumberland Pharmaceuticals	Phase 3
Completed	Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphyloc NCT00124020	Cumberland Pharmaceuticals	Phase 3
Completed	Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia NCT00081575	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3
Completed	Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia NCT00079885	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3
Completed	Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia NCT00080496	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3
Completed	Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired NCT00451386	Merck Sharp & Dohme LLC	Phase 2